Oncoceutics Receives Foundation Grants to Establish an Expanded Access Program for ONC201
The Onc-201 expanded access program is open again. We (the Musella Foundation) contributed $25,000 to help get this reopened, but we are no longer running the program. This is for people with DIPG or DMG with the H3K27M mutation!
Posted on: 11/05/2020 [Click the link below for full article]